Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study

Immune checkpoint inhibitor-related encephalitis (ICI-encephalitis) is not well characterised and diagnostic and prognostic biomarkers are lacking. We aimed to comprehensively characterise ICI-encephalitis and identify diagnostic biomarkers and outcome predictors. This retrospective observational st...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet regional health. Europe 2024-09, Vol.44, p.101011, Article 101011
Main Authors: Farina, Antonio, Villagrán-García, Macarena, Fourier, Anthony, Pinto, Anne-Laurie, Chorfa, Fatima, Timestit, Noémie, Alberto, Tifanie, Aupy, Jérôme, Benaiteau, Marie, Birzu, Cristina, Campetella, Lucia, Cotton, François, Dalle, Stéphane, Delaruelle, Clara Fontaine, Dumez, Pauline, Germi, Rafaele, Le Maréchal, Marion, Maillet, Denis, Marignier, Romain, Pegat, Antoine, Psimaras, Dimitri, Rafiq, Marie, Picard, Géraldine, Desestret, Virginie, Quadrio, Isabelle, Honnorat, Jérôme, Joubert, Bastien
Format: Article
Language:English
Subjects:
Adverse events
Autoimmune encephalitis
Biomarkers
Cancer
Cancer immunotherapy
Encephalitis
Immune checkpoint inhibitors
Life Sciences
Neural antibodies
Neurological immune-related adverse events
Paraneoplastic neurological syndromes
Prognostic factors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint inhibitor-related encephalitis (ICI-encephalitis) is not well characterised and diagnostic and prognostic biomarkers are lacking. We aimed to comprehensively characterise ICI-encephalitis and identify diagnostic biomarkers and outcome predictors. This retrospective observational study included all patients with ICI-encephalitis studied in the French Reference Centre on Paraneoplastic Neurological Syndromes (PNS) and Autoimmune Encephalitis (2015–2023). ICI encephalitis was considered definite in case of inflammatory findings at paraclinical tests and/or well-characterised neural antibodies. Predictors of immune-related adverse event (irAE) treatment response, defined as a Common Terminology Criteria for Adverse Events v5.0 grade 
ISSN:2666-7762
2666-7762
DOI:10.1016/j.lanepe.2024.101011